Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Trimethobenzamide is a potent antiemetic agent primarily utilized in the management of nausea and vomiting associated with various clinical conditions. Chemically classified as a benzamide derivative, its molecular formula is C21H26N2O4, and it carries the CAS Registry Number 98-05-3. The compound features a complex structure containing two methoxy groups attached to a benzene ring, which contributes significantly to its pharmacological activity. Structurally, it consists of a diethylaminoethoxy group linked to a dimethoxybenzoyl moiety, forming a stable molecule suitable for oral administration in tablet or capsule forms.
The primary therapeutic application of Trimethobenzamide lies in its ability to suppress the chemoreceptor trigger zone (CTZ) located in the area postrema of the brainstem. By blocking dopamine D2 receptors, it effectively inhibits the signals that induce vomiting, making it valuable for treating nausea caused by gastrointestinal disorders, surgical procedures, radiation therapy, or chemotherapy. Unlike some other antiemetics, it does not possess significant anticholinergic or sedative properties at standard therapeutic doses, although mild drowsiness may occur in some patients. It is often prescribed when other treatments have failed or are contraindicated.
Pharmacokinetically, the drug is well-absorbed from the gastrointestinal tract, reaching peak plasma concentrations within one to two hours after ingestion. It undergoes extensive first-pass metabolism in the liver, producing active metabolites that contribute to its duration of action. The elimination half-life varies but generally supports dosing schedules ranging from three to four times daily depending on the severity of symptoms. While generally safe, caution is advised for patients with hepatic impairment or those taking other central nervous system depressants. Common side effects include dizziness, drowsiness, and dry mouth, while rare instances of extrapyramidal symptoms have been reported, particularly in pediatric populations. Despite the availability of newer agents like ondansetron, Trimethobenzamide remains a relevant option in specific clinical scenarios due to its distinct mechanism of action and established safety profile over decades of use.